
Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
PFE | NYSE | USD | Real-time | |
PFE | Mexico | MXN | Delayed | |
PFE | Stockholm | SEK | Real-time | |
PFE | Frankfurt | EUR | Delayed | |
PFE | TradeGate | EUR | Delayed | |
PFE | Hamburg | EUR | Delayed | |
PFE | Xetra | EUR | Delayed | |
PFE | Santiago | USD | Delayed | |
PFE | Buenos Aires | ARS | Delayed | |
PFIZ34 | BM&FBovespa | BRL | Delayed | |
PFE | Vienna | EUR | Delayed | |
PFE_KZ | KASE | USD | Delayed | |
PFE | Colombia | COP | Delayed | |
PFE | Lima | USD | Delayed |
Biotechnology sector-related exchange traded funds continued to rally Friday on reports that Pfizer Inc. (NYSE: PFE) is looking to acquire Global Blood Therapeutics (NasdaqGS: GBT). On Friday, the...
Pfizer Inc (NYSE: PFE) is reportedly in advanced talks to buy Global Blood Therapeutics Inc (NASDAQ: GBT) for about $5 billion, bolster its portfolio and pipeline. Global Blood Therapeutics markets...
By Sam Boughedda Pfizer (NYSE:PFE) is reportedly in talks to acquire Global Blood Therapeutics Inc (NASDAQ:GBT), according to a report by The Wall Street Journal Friday. The news follows...
Shares of Global Blood Therapeutics Inc. jumped 9.5% in trading on Friday after The Wall Street Journal reported that Pfizer Inc. is considering buying the company for about $5 billion. There were...
(Reuters) – Pfizer Inc is in advanced talks to buy drugmaker Global Blood Therapeutics for about $5 billion, the Wall Street Journal reported on Friday, citing people familiar with the matter.
Acquiring the maker of a recently approved drug for sickle-cell disease would be the latest move by the drug giant to bolster its portfolio and pipeline.
Pfizer Inc (NYSE: PFE) announced that an interim futility analysis of the global Phase 3 trial, REALM-DCM of PF-07265803, indicated the trial is unlikely to meet its primary endpoint upon...
'We need vaccines with longer duration and greater breadth of protection,' said Dr. David Kessler, chief science officer for the White House’s COVID-19 response team.
By Sam Boughedda Pfizer (NYSE:PFE) topped estimates when it reported earnings for the second quarter premarket Thursday. The drugmaker reported a profit of $2.04 per share, $0.33 better than the...
Global biopharmaceutical behemoth Pfizer Inc. (PFE) has delivered a better-than-anticipated second-quarter performance on both its top-line and bottom-line. Driven by the robust performance of...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review